Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.

Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital; School of Medicine, Chang Gung University, Taoyuan.
Early Intervention in Psychiatry (Impact Factor: 1.65). 07/2012; DOI: 10.1111/j.1751-7893.2012.00379.x
Source: PubMed

ABSTRACT AIMS: The study aims to determine the clinical outcomes of aripiprazole treatment in adolescents and young adults with schizophrenia spectrum disorders. METHODS: This was a 24-week, observational, prospective study. Patients with schizophrenia spectrum disorders were prescribed a daily dose of 5 mg to 30 mg of aripiprazole. Effectiveness was assessed by the change from baseline in psychotic symptoms and quality of life. RESULTS: Forty-two patients with a mean age of 18.1 ± 3.7 years were recruited. Eighteen were experiencing the first episode of psychosis (FEP), whereas the remaining 24 were non-FEP. Psychotic symptoms, but not quality of life, improved globally from baseline scores by the endpoint of the study (effect size = 0.44). Compared with non-FEP patients, FEP patients had greater improvements (effect size = 0.45) in some clinical outcome dimensions during the 24-week aripiprazole treatment. CONCLUSION: We observed significant improvements of medium effect sizes in psychotic symptoms of patients with schizophrenia spectrum disorders within a naturalistic clinical setting, especially for FEP patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short structured diagnostic interview, developed jointly by psychiatrists and clinicians in the United States and Europe, for DSM-IV and ICD-10 psychiatric disorders. With an administration time of approximately 15 minutes, it was designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings. The authors describe the development of the M.I.N.I. and its family of interviews: the M.I.N.I.-Screen, the M.I.N.I.-Plus, and the M.I.N.I.-Kid. They report on validation of the M.I.N.I. in relation to the Structured Clinical Interview for DSM-III-R, Patient Version, the Composite International Diagnostic Interview, and expert professional opinion, and they comment on potential applications for this interview.
    The Journal of Clinical Psychiatry 02/1998; 59 Suppl 20:22-33;quiz 34-57. · 5.81 Impact Factor
  • Psychopharmacology bulletin 05/1982; 18(2):10-6. · 1.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews the management of schizophrenia occurring during childhood and adolescence. It considers the clinical features of the disorder particular to its early onset before providing a practical framework for assessment and treatment based upon a critical review of the available literature. A multi-modal approach to treatment encompassing the individual and their family is adopted with the roles of pharmacological, psychological, and environmental interventions all considered. The place of the newer "atypical" antipsychotic agents and the likelihood that they will soon become the first-line drugs of choice is particularly discussed.
    Journal of Child Psychology and Psychiatry 12/1998; 39(8):1071-81. · 5.42 Impact Factor


Available from
May 28, 2014